Telum Therapeutics, a biotechnology company leveraging proprietary metagenomic datasets, synthetic biology and generative AI to develop novel antimicrobial therapies, today announced the successful completion of… Read More »Telum Therapeutics Secures €18 Million Series A Financing to Advance Lead Antimicrobial Program into Clinical Development
In observance of World Health Day on April 7th, Telum Therapeutics announces its membership in the United Nations Global Compact as a new participant. The… Read More »Telum Therapeutics joins the United Nations Global Compact
Telum Therapeutics announces the appointment of Subhendu Basu, PhD, as its new Chief Executive Officer (CEO). He joins the company to lead it into its… Read More »Telum Therapeutics appoints Dr. Subhendu Basu as CEO
Telum Therapeutics has just received good news: a badge for its social, environmental and ethical commitment awarded by EcoVadis, the world’s most trusted provider of… Read More »Telum Therapeutics earns EcoVadis badge for corporate sustainability
Telum Therapeutics has joined the Treedom platform, which is part of the B corp community, to help create sustainable agroforestry ecosystems and fight climate change.… Read More »Telum Therapeutics joins forces with Treedom to plant 100 trees
Telum Therapeutics has become a member of the Spanish Bioindustry Association (Asebio), which strategically promotes the Spanish biotechnology sector and includes more than 300 companies,… Read More »Telum Therapeutics joins Spanish Bioindustry Association
Telum Therapeutics announced today the appointment of Professor Vincent A. Fischetti, that has introduced phage lysins as a new antimicrobial therapy and an alternative to… Read More »Telum Therapeutics names Vincent A. Fischetti chairman of its Scientific Advisory Board
